Colorectal Cancer Molecular Diagnostics Global Market 2024 – Driving Factors, Industry Challenges, Business segmentation, Leading countries And Forecast To 2033

Colorectal Cancer Molecular Diagnostics Global Market

The Colorectal Cancer Molecular Diagnostics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Colorectal Cancer Molecular Diagnostics Market:
https://www.thebusinessresearchcompany.com/report/colorectal-cancer-molecular-diagnostics-global-market-report

According to The Business Research Company’s Colorectal Cancer Molecular Diagnostics Global Market Report 2024, The colorectal cancer molecular diagnostics market size has grown strongly in recent years. It will grow from $2.35 billion in 2023 to $2.56 billion in 2024 at a compound annual growth rate (CAGR) of 9.2%.  The  growth in the historic period can be attributed to increasing incidence of colorectal cancer, growing awareness and screening initiatives, rising emphasis on personalized medicine, government initiatives for cancer control..

The colorectal cancer molecular diagnostics market size is expected to see strong growth in the next few years. It will grow to $3.48 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%.  The growth in the forecast period can be attributed to aging population and increased risk factors, integration of genomic data into clinical practice, rise in precision medicine approaches, global efforts in cancer research and collaboration.. Major trends in the forecast period include increasing emphasis on early detection biomarkers, integration of artificial intelligence (ai) in data analysis, rise of circulating tumor dna (ctdna) analysis, expansion of companion diagnostics for targeted therapies, focus on immunotherapy biomarkers..

The increasing incidence of inflammatory bowel diseases (IBD) is expected to propel the growth of the colorectal cancer molecular diagnostic market going forward. Inflammatory bowel diseases (IBD) are chronic gastrointestinal disorders characterized by digestive tract inflammation, primarily affecting the colon and rectum, with symptoms like abdominal pain, diarrhea, and weight loss, managed through medications, lifestyle changes, and sometimes surgery. The increasing incidence of inflammatory bowel diseases fuels the demand for accurate, efficient, and advanced diagnostic solutions that play an essential role, as the determination of systemic therapy for colorectal cancer (CRC) predominantly relies on the result obtained from molecular assessment of the tumor. For instance, in May 2021, according to BioMed Central Ltd., a UK-based scientific open-access publisher, the number of inflammatory bowel disease (IBD) cases is projected to increase 2.5 times compared to 2020, with approximately 69,000 cases in Iran, 220,000 cases in the Middle East, 2.2 million cases in India, and a significant 4.5 million cases in East Asia during 2020–2035. Therefore, increasing incidences of inflammatory bowel diseases (IBD) will drive the growth of the colorectal cancer molecular diagnostic market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=13120&type=smp

The colorectal cancer molecular diagnostics market covered in this report is segmented –

1) By Type: Instruments, Reagents And Kits, Services

2) By Technology: Polymerase Chain Reaction (PCR), Sequencing, Mass Spectrometry, Transcription Mediated Amplification, Chips And Microarrays, Isothermal Nucleic Acid Amplification Technology (INAAT)

3) By End Users: Hospitals, Ambulatory Surgical Centers, Diagnostic Laboratories, Homecare Settings

Top Major Players
Johnson & Johnson
Bayer A
Abbott Laboratories
Danaher Corporation
Becton Dickinson and Company

Major companies operating in the colorectal cancer molecular diagnostic market focus on developing innovative molecular diagnostics and personalized medicine solutions, such as the shield blood test approach to identify colorectal cancer at an earlier, more treatable stage. Shield Blood Test, an initial blood test designed to identify early-stage colorectal cancer (CRC). For instance, in May 2022, Guardant Health, a US-based biotechnology company offering oncology molecular diagnostic products, launched its Shield Blood Test. The susceptible shield test provides a convenient screening option that involves a simple blood draw to address challenges related to patients’ willingness to get screened. The test showed a sensitivity of 91% for detecting colorectal cancer and 20% for detecting advanced adenomas, and the specificity was measured at 92%. The Shield test identifies early colorectal cancer signals in the blood by utilizing data from diverse cohorts of over 2,000 subjects with colorectal cancer, 357 with advanced adenoma, and 3,757 normal subjects.

The colorectal cancer molecular diagnostics market report table of contents includes:
1. Executive Summary
2. Colorectal Cancer Molecular Diagnostics Market Characteristics
3. Colorectal Cancer Molecular Diagnostics Market Trends And Strategies
4. Colorectal Cancer Molecular Diagnostics Market – Macro Economic Scenario
5. Global Colorectal Cancer Molecular Diagnostics Market Size and Growth
………………………..
32. Global Colorectal Cancer Molecular Diagnostics Market Competitive Benchmarking
33. Global Colorectal Cancer Molecular Diagnostics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Colorectal Cancer Molecular Diagnostics Market
35. Colorectal Cancer Molecular Diagnostics Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model